Archives     Advertise     Editorial Calendar     Subscribe     Contact Us    



Vanderbilt Takes Investigational New Drug From Bench To Bedside


 
P. Jeffrey Conn, PhD

Patients with serious brain disorders such as Alzheimer's disease and schizophrenia could benefit from an investigational new drug (IND) that has received notification from the FDA that testing in humans may proceed after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

"This is the first instance I am aware of where an academic drug discovery group moved a molecule for treatment of chronic brain disorders all the way from early discovery to human trials without there being, at some point along the way, a pharmaceutical partner," said P. Jeffrey Conn, PhD, director, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD). "And that really is crossing what people refer to all of the time as the 'Valley of Death,' where good research discoveries have a hard time moving into the real testing phase."

For Alzheimer's disease, the IND targets major pathologies of the disease and offers highly selective activation of a key receptor unlike the current standard of care, cholinesterase inhibitors. Vanderbilt researchers said the molecule might be broadly effective across a number of cognitive and neuropsychiatric disorders. In schizophrenia, current treatments address the positive symptoms of the disease, including hallucinations and delusions, but not the negative symptoms and cognitive disturbances of schizophrenia. "People who treat schizophrenia patients commonly agree that the negative symptoms and cognitive disturbances are the major factors that decrease the ability for these patients to integrate in society," Conn said. "And we have no treatments for those so our hope is that this molecule will be effective."

VCNDD Co-Director Craig W. Lindsley, PhD, director of Medicinal Chemistry and the William K. Warren, Jr. Chair in Medicine, said phase I testing will assess drug safety and tolerability in young healthy volunteers, a process that could take a year. If successful, the phase II and III studies would include patients with either Alzheimer's disease or schizophrenia and could take three-five years to complete.

 
Share:

Related Articles:


Recent Articles

AMA Announces New Online Education to Help Physicians Use and Interpret Cancer Panel Testing in Practice

As part of its program aimed at educating physicians and other health care professionals on the benefits and limitations of genomics and precision medicine, the American Medical Association (AMA) today announced two new online educational modules focused on somatic cancer panel testing.

Read More

IQuity Expands Nationally, Hires Four

Nashville-based IQuity, a diagnostic firm analyzing RNA data, announced four new hires last month.

Read More

Rapid RNA Testing Dials Up Quicker Diagnostics

The sooner you know, the sooner you can act - advances in RNA diagnostics are helping providers identify disease more rapidly and move to the treatment phase.

Read More

Death Master Crime Fighters

You don't have to be a superhero to fight fraud with the Death Master File ... but you do have to be certified.

Read More

A Sense of Security

The IRS has announced the first 84 CPEOs in the nation ... and one of them is headquartered in Nashville.

Read More

Reforming Healthcare Reform

The Senate has now weighed in on their version of ACA 'repeal and replace.' Will it fare better with public sentiment than AHCA has so far?

Read More

Staying Compliant by Avoiding Complacency

A new presidential administration doesn't mean the long list of DOJ regulations impacting healthcare has gone to the wayside. Instead, federal agents continue to up their game when it comes to cracking down on fraud, Stark violations.

Read More

ProviderTrust Helps Employers Keep Compliant by Monitoring Who Isn't

ProviderTrust monitors employees post-hire to keep companies out of hot water.

Read More

ProviderTrust Helps Employers Keep Compliant by Monitoring Who Isn't

ProviderTrust monitors employees post-hire to keep companies out of hot water.

Read More

ProviderTrust Helps Employers Keep Compliant by Monitoring Who Isn't

ProviderTrust monitors employees post-hire to keep companies out of hot water.

Read More

Email Print
 
 

 

 


Tags:
None
Powered by Bondware
News Publishing Software

The browser you are using is outdated!

You may not be getting all you can out of your browsing experience
and may be open to security risks!

Consider upgrading to the latest version of your browser or choose on below: